SCHEMBL93982

SCHEMBL93982

[CH2]Cc1ccc(Cl)c(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 4/20 0.58
▸ PNMT P11086 2/20 0.54
▸ TAAR1 Q96RJ0 1/20 0.54
▸ SIGMAR1 Q99720 3/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ IGF1R P08069 1/20 0.45
▸ ALOX15 P16050 1/20 0.45
▸ AHR P35869 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ FDPS P14324 1/20 0.42
▸ TSHR P16473 1/20 0.42
▸ SLC6A2 P23975 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ RAB9A P51151 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9455806 0.80 IDO1 (0.38) IDO1PNMTTAAR1SIGMAR1SLC6A2
SCHEMBL3565937 0.80 PNMT (0.61) IDO1PNMTTAAR1SIGMAR1IGF1R
SCHEMBL5805041 0.79 IDO1 (0.58) IDO1PNMTTAAR1SIGMAR1SMN1; SMN2
SCHEMBL3763570 0.78 CYP3A4 (0.46) IDO1SMN1; SMN2ALOX15TSHRNPC1
SCHEMBL5085456 0.78 IDO1 (0.37) IDO1PNMTTAAR1SIGMAR1
SCHEMBL27719648 0.78 CA2 (0.57) IGF1RALOX15TSHR
SCHEMBL151278 0.78 PIK3CA (0.44) PNMTTAAR1TSHRLMNAHTT
SCHEMBL3746892 0.78 MAPT (0.45) IDO1PNMTTAAR1SLC6A2SLC6A4
SCHEMBL3753927 0.78 S1PR1 (0.38) IDO1PNMTTAAR1SMN1; SMN2NPC1
SCHEMBL5085475 0.78 IDO1 (0.37) IDO1PNMTTAAR1SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 738 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240207253-A1 Inhibitors of CDR1 for Reversal of Azole Drug Resistance in Fungal Infections THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS 2024-06-27 — — US claimed
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-11-02 — — US claimed
US-20230174486-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2023-06-08 — — US claimed
CN-115867534-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2023-03-28 — — CN claimed
EP-4146623-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 — — EP claimed
EP-4146624-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF Alectos Therapeutics Inc. (CA) 2023-03-15 — — EP claimed
CN-115803025-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2023-03-14 — — CN claimed
WO-2022245951-A1 INHIBITORS OF CDR1 FOR REVERSAL OF AZOLE DRUG RESISTANCE IN FUNGAL INFECTIONS UNM RAINFOREST INNOVATIONS (US) 2022-11-24 — — WO claimed
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF ALECTOS THERAPEUTICS INC. (CA) 2022-07-07 — — US claimed
CN-114174263-A Non-lysosomal glucosylceramidase inhibitors and uses thereof 阿勒克图治疗公司 2022-03-11 — — CN claimed
WO-2000032588-A2 CARBOXYLIC ACIDS AND CARBOXYLIC ACID ISOSTERES OF N-HETEROCYCLIC COMPOUNDS GPI NIL HOLDINGS, INC. (US) 2000-06-08 — — WO claimed
WO-1999062881-A1 AZA-HETEROCYCLIC COMPOUNDS USED TO TREAT NEUROLOGICAL DISORDERS AND HAIR LOSS GPI NIL HOLDINGS, INC. (US) 1999-12-09 — — WO claimed
EP-0922050-A1 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1999-06-16 — — EP claimed
US-5786448-A FOR SCREENING, SYNTHESIZING PEPTIDE DERIVATIVES TREGA BIOSCIENCES, INC. (US) 1998-07-28 — — US claimed
US-5750510-A ANTIBIOTICS ABBOTT LABORATORIES (US) 1998-05-12 — — US claimed
WO-1997042205-A1 3-DESCLADINOSE-2,3-ANHYDROERYTHROMYCIN DERIVATIVES ABBOTT LABORATORIES (US) 1997-11-13 — — WO claimed
EP-0767174-A1 Novel aminoalkanephosphinic acids and their salts CIBA-GEIGY AG (CH) 1997-04-09 — — EP claimed
US-5376684-A Aminobutyric acid antagonist; antiepileptic agent CIBA-GEIGY CORPORATION (US) 1994-12-27 — — US claimed
EP-0543780-A2 Novel aminoalkanephosphinic acids and their salts CIBA-GEIGY AG (CH) 1993-05-26 — — EP claimed
EP-0031104-A1 Thiazolidine compounds, processes for their preparation and pharmaceutical compositions containing them SANTEN PHARMACEUTICAL CO., LTD. (JP) 1981-07-01 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348387-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA IDO1 2392/4885PNMT 3313/4885TAAR1 4166/4885
US-20220213058-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA IDO1 2392/4885PNMT 3313/4885TAAR1 4166/4885
US-20240207253-A1 Inhibitors of CDR1 for Reversal of Azole Drug Resistance in Fungal Infections ABCC1, ABCC2, ERG28 IDO1 1065/4885PNMT 3065/4885TAAR1 3116/4885
US-20230174486-A1 NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF GBA1, GBA2, GAA IDO1 2392/4885PNMT 3313/4885TAAR1 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback